Search

Your search keyword '"Laskin, J."' showing total 454 results

Search Constraints

Start Over You searched for: Author "Laskin, J." Remove constraint Author: "Laskin, J." Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
454 results on '"Laskin, J."'

Search Results

1. Whole-genome and transcriptome analysis enhances precision cancer treatment options

2. Molecular composition of particulate matter emissions from dung and brushwood burning household cookstoves in Haryana, India

3. Effect of relative humidity on the composition of secondary organic aerosol from the oxidation of toluene

4. Molecular Diversity of Sea Spray Aerosol Particles: Impact of Ocean Biology on Particle Composition and Hygroscopicity

6. Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

7. Complex refractive indices in the near-ultraviolet spectral region of biogenic secondary organic aerosol aged with ammonia

8. Effect of humidity on the composition of isoprene photooxidation secondary organic aerosol

11. Immune Activation following Irbesartan Treatment in a Colorectal Cancer Patient: A Case Study

13. LBA4 Preliminary safety and efficacy of adagrasib with pembrolizumab in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation

16. EP04.02-004 The Patient Impact of Liquid Biopsy - Health-Related Quality of Life in Patients Undergoing Liquid Biopsy for Advanced Non-Small Cell Lung Cancer

17. EP08.02-108 Osimertinib Long-Term Tolerability in Patients with EGFRm NSCLC Enrolled in the AURA Program or FLAURA Study

20. OA16.02 The Economic Value of Liquid Biopsy for Genomic Profiling in Advanced Non-Small Cell Lung Cancer

27. P89.03 Demonstrating VALUE of Liquid Biopsy for Lung Cancer in a Public Healthcare System

30. 1195P The value of detecting resistance through liquid biopsy

31. Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)

35. Canadian Consensus: Oligoprogressive, Pseudoprogressive, and Oligometastatic Non-Small-Cell Lung Cancer

36. FUS-NFATc2 sarcoma of bone, a novel molecular entity with aggressive behavior: Clinical and molecular pathology findings of two cases

37. ASTRIS real world study of osimertinib in patients (pts) with EGFR T790M NSCLC: Efficacy analysis by tissue or plasma T790M test

38. Personalized oncogenomics in the management of gastrointestinal carcinomas&mdash

45. OA 10.01 Detection of EGFR mutations from plasma ctDNA in the osimertinib Phase III trial (AURA3): comparison of three plasma assays

47. P3.01-019 Canadian Multicenter Validation Study of Plasma Circulating Tumor DNA for Epidermal Growth Factor (EGFR) T790M Testing

48. P3.01-062 The Perceived Value of Avoiding Biopsy: Patients' Willingness to Pay for Circulating Tumor DNA T790M Testing

Catalog

Books, media, physical & digital resources